Hema-NeoTIL01 cell therapy for relapsed or refractory acute leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new cell therapy called Hema-NeoTIL01 for people whose B-ALL or AML leukemia has come back or stopped responding to treatment. It aims to find out if these special immune cells can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 69 years old.
- You have B-cell acute lymphoblastic leukemia (B-ALL) or acute myeloid leukemia (AML) that has returned or is not responding to standard treatments.
- You have tried chemotherapy but it did not work, or the leukemia came back after treatment.
- If you had CAR-T cell therapy before and it did not work or the leukemia came back, you may still join.
- Your heart, liver, kidneys, and lungs are working well enough based on tests.
- You are not pregnant and agree to use birth control for one year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (QH103) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses specially modified immune cells to find and kill cancer cells that have a protein called CD19 on their surface.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new CAR-T cell treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. It aims to see if these immune cells can safely and effectively fight the cancer.
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
This trial tests a new cell therapy (BG1805) for children whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The therapy targets a specific marker on leukemia cells called CLL-1 and aims to help the immune system fight the cancer.
This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.